AE Wealth Management LLC Has $345,000 Holdings in Zoetis Inc. (NYSE:ZTS)

AE Wealth Management LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 9.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,988 shares of the company’s stock after acquiring an additional 172 shares during the period. AE Wealth Management LLC’s holdings in Zoetis were worth $345,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Webster Bank N. A. lifted its position in Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares during the period. Neo Ivy Capital Management bought a new stake in Zoetis during the fourth quarter worth about $40,000. LRI Investments LLC bought a new stake in Zoetis during the first quarter worth about $43,000. Ables Iannone Moore & Associates Inc. bought a new stake in Zoetis during the fourth quarter worth about $51,000. Finally, Hazlett Burt & Watson Inc. lifted its position in Zoetis by 60.7% during the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock worth $46,000 after purchasing an additional 102 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Stifel Nicolaus upped their price objective on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. BTIG Research increased their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Finally, Piper Sandler increased their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average price target of $220.38.

Zoetis Stock Down 0.1 %

Shares of NYSE ZTS opened at $194.70 on Friday. The company has a 50 day simple moving average of $185.72 and a 200 day simple moving average of $174.76. The firm has a market cap of $88.84 billion, a PE ratio of 37.51, a price-to-earnings-growth ratio of 2.97 and a beta of 0.88. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The business had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the business earned $1.41 EPS. On average, research analysts forecast that Zoetis Inc. will post 5.84 EPS for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.